TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Castleman disease (CD) encompasses rare lymphoproliferative disorders with shared lymph node pathology but diverse clinical presentations.
• Unicentric CD (UCD) affects one lymph node region, while Multicentric CD (MCD) involves multiple regions, systemic symptoms, and organ dysfunction.
• MCD is classified as HHV-8-associated or HHV-8-negative/idiopathic (iMCD), with iMCD further sub-divided.

Purpose of the Study:

• To clarify the sub-classifications of idiopathic Multicentric Castleman disease (iMCD).
• To differentiate between iMCD with TAFRO syndrome and non-TAFRO iMCD.
• To highlight potential prognostic differences between iMCD subtypes.

Main Methods:

• Review and synthesis of existing literature on Castleman disease classifications.
• Comparative analysis of clinical and laboratory features distinguishing iMCD subtypes.
• Identification of key diagnostic criteria for TAFRO syndrome within iMCD.

Main Results:

• Idiopathic MCD (iMCD) is now sub-divided into TAFRO syndrome and non-TAFRO iMCD.
• TAFRO syndrome is characterized by thrombocytopenia, anasarca, fevers, reticulin myelofibrosis, and organomegaly, with normal or low immunoglobulin levels.
• Non-TAFRO iMCD typically presents with thrombocytosis, milder fluid retention, and hypergammaglobulinemia.

Conclusions:

• The distinction between TAFRO and non-TAFRO iMCD is crucial for understanding disease heterogeneity.
• iMCD patients with TAFRO syndrome may face a poorer prognosis, warranting further investigation.
• Further research is essential to fully elucidate the clinical implications and management strategies for iMCD subtypes.